Efficacy and clinical cases of tepotinib (Tuodekang) in the treatment of patients with rare MET mutations

Tepotinib is a selective MET tyrosine kinase inhibitor, mainly used to treat patients with MET exon 14 skipping Patients with non-small cell lung cancer (NSCLC) with skipping) mutations. Although the incidence of this type of mutation is relatively low in advanced lung cancer, it responds significantly to targeted therapy. Tepotinib inhibits tumor cell proliferation and metastasis by blocking the MET signaling pathway, providing a new treatment option for patients with rare MET mutations.

Clinical studies have shown that tepotinib has a high efficacy in patients with METexon14 skipping mutations. The results of multiple I/II phase clinical trials have shown that the objective response rate (ORR) of patients treated with tepotinib is approximately 40% to 50%, and the disease control rate (DCR) can reach more than 70%, and the median progression-free survival (PFS) is about 8 to 12 months. These data demonstrate that tepotinib has significant advantages in delaying disease progression and improving patients' quality of life.

In terms of clinical cases, a patient with advanced METExon14 mutationNSCLC received tepotinib treatment. Imaging examination showed that the tumor shrank significantly, symptoms such as cough and dyspnea were improved, and the quality of life was significantly improved. Another patient with a rare MET mutation further reduced the tumor burden after receiving tepotinib combined with local radiotherapy, and tolerated the treatment well, with only mild edema and mild gastrointestinal discomfort. These cases provide strong support for the application of tepotinib in real clinical settings.

It is worth noting that the safety profile of tepotinib is generally good, but it is still necessary to pay attention to adverse reactions such as mild edema, gastrointestinal discomfort, and abnormal liver function during treatment. Clinically, side effects are usually controlled through dose adjustment and symptom management, while tumor imaging changes are regularly followed up to ensure maximum efficacy. Taken together, tepotinib is rarePatients with MET mutations provide new options for targeted therapy, whose efficacy and safety have been verified in both real-world and clinical trials.

Reference materials:https://www.drugs.com/